| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MBNL1 |
| Uniprot No | Q9NR56 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-382aa |
| 氨基酸序列 | MAVSVTPIRDTKWLTLEVCREFQRGTCSRPDTECKFAHPSKSCQVENGRVIACFDSLKGRCSRENCKYLHPPPHLKTQLEINGRNNLIQQKNMAMLAQQMQLANAMMPGAPLQPVPMFSVAPSLATNASAAAFNPYLGPVSPSLVPAEILPTAPMLVTGNPGVPVPAAAAAAAQKLMRTDRLEVCREYQRGNCNRGENDCRFAHPADSTMIDTNDNTVTVCMDYIKGRCSREKCKYFHPPAHLQAKIKAAQYQVNQAAAAQAAATAAAMGIPQAVLPPLPKRPALEKTNGATAVFNTGIFQYQQALANMQLQQHTAFLPPGSILCMTPATSVVPMVHGATPATVSAATTSATSVPFAATATANQIPIISAEHLTSHKYVTQM |
| 预测分子量 | 53.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MBNL1重组蛋白的3篇示例参考文献(内容为模拟，建议通过学术数据库核实真实文献)：
---
1. **文献名称**：*"Recombinant MBNL1 rescues splicing defects in myotonic dystrophy cellular models"*
**作者**：Jones et al.
**摘要**：研究通过在大肠杆菌中表达重组人源MBNL1蛋白，验证其在体外恢复强直性肌营养不良症(DM1)细胞模型中异常剪接事件的能力，证明其功能活性可用于潜在治疗策略开发。
2. **文献名称**：*"Structural and functional analysis of MBNL1 protein domains using recombinant variants"*
**作者**：Chen & Smith
**摘要**：利用重组表达的MBNL1截短体蛋白，解析其锌指结构域与RNA结合的分子机制，揭示了不同结构域在调控靶标RNA选择性剪接中的协同作用。
3. **文献名称**：*"High-yield purification of MBNL1 recombinant protein and its application in RNA interaction studies"*
**作者**：Wang et al.
**摘要**：报道了一种高效纯化重组MBNL1蛋白的方法，结合凝胶迁移实验(EMSA)和CLIP-seq技术，系统鉴定了其RNA结合偏好性，为疾病相关突变体的功能研究提供工具。
---
如需真实文献，建议通过 **PubMed** 或 **Google Scholar** 检索关键词(如“MBNL1 recombinant protein”或“MBNL1 expression purification”)。
MBNL1 (Muscleblind-like protein 1) is an RNA-binding protein critical for regulating alternative splicing, RNA localization, and stability in mammalian cells. It belongs to the Muscleblind-like (MBNL) family, which is evolutionarily conserved and characterized by tandem zinc finger domains that recognize specific RNA motifs, particularly GC-rich sequences or YGCY (where Y = pyrimidine) elements in pre-mRNA targets. MBNL1 plays a key role in developmental transitions, such as muscle and neuronal differentiation, by modulating splicing events that control tissue-specific functions.
Dysregulation of MBNL1 is strongly associated with myotonic dystrophy (DM), a multisystemic disorder caused by expanded CUG or CCUG repeat sequences in non-coding regions of *DMPK* or *CNBP* genes. These repeats sequester MBNL1 into nuclear foci, depleting its availability for normal RNA processing. This loss of function leads to mis-splicing of numerous transcripts, contributing to DM symptoms like myotonia, muscle wasting, and insulin resistance.
Recombinant MBNL1 proteins are engineered to study its molecular interactions and rescue splicing defects in disease models. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), these proteins retain functional domains, enabling biochemical assays (e.g., RNA-binding studies) or therapeutic exploration. For instance, recombinant MBNL1 has been used to validate small molecules designed to disrupt toxic RNA-MBNL1 interactions in DM. Additionally, structural studies using recombinant protein have elucidated mechanisms of RNA recognition, informing strategies to enhance splicing correction.
Research on MBNL1 continues to advance gene therapy approaches, including overexpression of recombinant MBNL1 to counteract sequestration in DM and restore normal RNA processing, highlighting its potential as a therapeutic target.
×
